EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs

CAMBRIDGE, Mass.–(BUSINESS WIRE)–EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced it has signed a memorandum of understanding (MOU) with the National Health Service in England (NHSE). The MOU signals the intention of NHSE and EQRx to enter into a long-term, strategic partnership to secure patient access to EQRx’s pipeline of innovative and cost-effective cancer medicines, contingent
Click here to view original post